Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Scott W Andersen"'
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119632 (2015)
One method for demonstrating disease modification is a delayed-start design, consisting of a placebo-controlled period followed by a delayed-start period wherein all patients receive active treatment. To address methodological issues in previous dela
Externí odkaz:
https://doaj.org/article/289605412a574e48872b12c4d00111bf
Autor:
Cynthia D. Evans, JonDavid Sparks, Scott W. Andersen, Dawn A. Brooks, Paula M. Hauck, Mark A. Mintun, John R. Sims
Publikováno v:
Alzheimer's & Dementia.
Autor:
Sergey Shcherbinin, Cynthia D. Evans, Ming Lu, Scott W. Andersen, Michael J. Pontecorvo, Brian A. Willis, Ivelina Gueorguieva, Paula M. Hauck, Dawn A. Brooks, Mark A. Mintun, John R. Sims
Publikováno v:
JAMA neurology. 79(10)
Importanceβ-amyloid plaques and neurofibrillary tau deposits biologically define Alzheimer disease.ObjectiveTo perform post hoc analyses of amyloid reduction after donanemab treatment and assess its association with tau pathology and clinical measur
Autor:
Christopher H. van Dyck, Roger Clarnette, Susan Mills, John C. Morris, Carlos Cruchaga, Anna Santacruz, Ging-Yuek Robin Hsiung, Roy Yaari, Suman Jayadev, Caroline Giacobino, William S. Brooks, Robert A. Koeppe, Raquel Sánchez-Valle, Anne M. Fagan, Eric McDade, Sarah B. Berman, Catherine J. Mummery, Florence Pasquier, Scott M. Berry, Randall J. Bateman, Brian A. Gordon, Jorge J. Llibre-Guerra, Maïté Formaglio, Paul S. Aisen, Paulo Fontoura, Mark A. Mintun, Bruno Dubois, Erik D. Roberson, Kelley Coalier, Ronald G. Thomas, Martin R. Farlow, John R. Sims, Serge Gauthier, Douglas Galasko, Mario Masellis, G. Mustafa Surti, Barbara A. Wendelberger, Guoqiao Wang, James J. Lah, Yan Li, David B. Clifford, David Wallon, Paul Delmar, Alison Goate, Rachelle S. Doody, Didier Hannequin, Stephen Salloway, Geoffrey A. Kerchner, Karen C. Holdridge, Ivonne Z. Jimenez-Velazquez, Janice M. Hitchcock, Monika Baudler, Lawrence S. Honig, Tammie L.S. Benzinger, Clifford R. Jack, Peter J. Snyder, Scott W. Andersen, J. Pariente, Andrew J. Aschenbrenner, Jason Hassenstab, Richard J. Perrin, Colin L. Masters, Chengjie Xiong, Jared R. Brosch, B. Joy Snider
Publikováno v:
Nat Med
Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes decades before the onset of clinical symptoms, enabling testing of interventions in the asymptomatic and symptomatic stages to delay or slow disease progression. We
Autor:
Cynthia Duggan Evans, Daniel Skovronsky, Paul A. Ardayfio, JonDavid Sparks, Mark A Mintun, Sergey Shcherbinin, Scott W. Andersen, Liana G. Apostolova, Miroslaw Brys, John R. Sims, Alette M. Wessels, Albert C. Lo, Stephen Salloway
Publikováno v:
New England Journal of Medicine. 384:1691-1704
Background A hallmark of Alzheimer’s disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for t...
Autor:
Mosun Ayan-Oshodi, Douglas E. James, Jennifer A. Zimmer, Brian A. Willis, Scott A. Monk, Scott W. Andersen, Alan R. Kugler, Jamie Mullen
Publikováno v:
The Journal of Clinical Pharmacology. 60:586-594
Lanabecestat, a novel β-site amyloid precursor protein-cleaving enzyme 1 inhibitor evaluated for Alzheimer treatment, inhibits P-glycoprotein (P-gp) activity in vitro. After oral 50-mg lanabecestat administration, gastric fluid lanabecestat concentr
Autor:
JonDavid Sparks, Albert C. Lo, Cynthia Duggan Evans, Saptarshi Chatterjee, Scott W. Andersen, John R. Sims, Mirek Brys, Mark A Mintun
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Sergey Shcherbinin, Scott W. Andersen, Cynthia Duggan Evans, Albert C. Lo, Ming Lu, Michael Navitsky, Emily C Collins, John R. Sims, Dawn A. Brooks, Mark A Mintun
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Leanne M Munsie, Albert C. Lo, Adam S Fleisher, Scott W. Andersen, Sergey Shcherbinin, John R. Sims, Mirek Brys, Mark A Mintun
Publikováno v:
Alzheimer's & Dementia. 17
Autor:
Diana O. Svaldi, Sergey Shcherbinin, Michael D. Devous, John R. Sims, John Landry, Sonja M. Bragg, Jamie Mullen, Jennifer A. Zimmer, Adam S. Fleisher, Alette M. Wessels, Scott W. Andersen, Katherine J. Selzler, Craig Shering, AnnCatherine M. Downing
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction Lanabecestat, a beta‐site amyloid precursor protein‐cleaving enzyme 1 (BACE1) inhibitor, was investigated as a potential Alzheimer's disease (AD)‐modifying treatment. As previously reported, amyloid beta (Aβ) neuritic plaque burde